Table S3.
Baseline characteristics of included studies on retinal vein occlusion
| Author | Year | Treatment | Age (years) | VA (ETDRS letters) | CMT (μm) | Follow-up (weeks) |
|---|---|---|---|---|---|---|
| Brown et al47 | 2010 | IVR 0.3, 0.5 mg vs sham | 67.57 | 48.3 | 685 | 24 |
| Campochiaro et al48 | 2010 | IVR 0.3, 0.5 mg vs sham | 66 | 54.6 | 520.5 | 24 |
| Kinge et al32 | 2010 | IVR 0.5 mg vs sham | 72 | 43 | 625 | 24 |
| Moradian et al49 | 2011 | IVB 1.25 mg vs sham | 57.6 | 38.45 | 525.17 | 12 |
Abbreviations: CMT, central macular thickness; IVR, intravitreal ranibizumab; IVB, intravitreal bevacizumab; VA, visual acuity; ETDRS, early treatment diabetic retinopathy study.